We previously observed that the ability of the competitive MOR antagonist naloxone to reverse buprenorphine-induced respiratory depression is reduced compared with reversal of fentanyl- and morphine-induced respiratory depression (7, 8, 16). This evidence concerns the gene OPRM1 and Respiratory insufficiency due to muscle weakness.